These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37048084)

  • 1. Unraveling the Role of Peroxisome Proliferator-Activated Receptor β/Δ (PPAR β/Δ) in Angiogenesis Associated with Multiple Myeloma.
    Leone P; Solimando AG; Prete M; Malerba E; Susca N; Derakhshani A; Ditonno P; Terragna C; Cavo M; Silvestris N; Racanelli V
    Cells; 2023 Mar; 12(7):. PubMed ID: 37048084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular PPARβ/δ Promotes Tumor Angiogenesis and Progression.
    Wagner KD; Du S; Martin L; Leccia N; Michiels JF; Wagner N
    Cells; 2019 Dec; 8(12):. PubMed ID: 31842402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients.
    Lamanuzzi A; Saltarella I; Ferrucci A; Ria R; Ruggieri S; Racanelli V; Rao L; Annese T; Nico B; Vacca A; Ribatti D
    Oncotarget; 2016 Mar; 7(12):14510-21. PubMed ID: 26919105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
    Babarović E; Valković T; Budisavljević I; Balen I; Štifter S; Duletić-Načinović A; Lučin K; Jonjić N
    Pathol Res Pract; 2016 Jun; 212(6):509-16. PubMed ID: 26997492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?
    Saltarella I; Frassanito MA; Lamanuzzi A; Brevi A; Leone P; Desantis V; Di Marzo L; Bellone M; Derudas D; Ribatti D; Chiaramonte R; Palano MT; Neri A; Mariggiò MA; Fumarulo R; Dammacco F; Racanelli V; Vacca A; Ria R
    Neoplasia; 2019 Jan; 21(1):93-105. PubMed ID: 30529074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
    Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
    Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
    Ria R; Catacchio I; Berardi S; De Luisi A; Caivano A; Piccoli C; Ruggieri V; Frassanito MA; Ribatti D; Nico B; Annese T; Ruggieri S; Guarini A; Minoia C; Ditonno P; Angelucci E; Derudas D; Moschetta M; Dammacco F; Vacca A
    Clin Cancer Res; 2014 Feb; 20(4):847-58. PubMed ID: 24297864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPAR Beta/Delta and the Hallmarks of Cancer.
    Wagner N; Wagner KD
    Cells; 2020 May; 9(5):. PubMed ID: 32375405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor-β/δ regulates angiogenic cell behaviors and oxygen-induced retinopathy.
    Capozzi ME; McCollum GW; Savage SR; Penn JS
    Invest Ophthalmol Vis Sci; 2013 Jun; 54(6):4197-207. PubMed ID: 23716627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.
    De Luisi A; Ferrucci A; Coluccia AM; Ria R; Moschetta M; de Luca E; Pieroni L; Maffia M; Urbani A; Di Pietro G; Guarini A; Ranieri G; Ditonno P; Berardi S; Caivano A; Basile A; Cascavilla N; Capalbo S; Quarta G; Dammacco F; Ribatti D; Vacca A
    Clin Cancer Res; 2011 Apr; 17(7):1935-46. PubMed ID: 21307145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
    Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
    Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombopoietin Promotes Angiogenesis and Disease Progression in Patients with Multiple Myeloma.
    Lamanuzzi A; Saltarella I; Frassanito MA; Ribatti D; Melaccio A; Desantis V; Solimando AG; Ria R; Vacca A
    Am J Pathol; 2021 Apr; 191(4):748-758. PubMed ID: 33516787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow angiogenesis in multiple myeloma.
    Vacca A; Ribatti D
    Leukemia; 2006 Feb; 20(2):193-9. PubMed ID: 16357836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of peroxisome proliferator-activated receptor-β/δ (PPAR-β/δ) inhibits human breast cancer cell line tumorigenicity.
    Yao PL; Morales JL; Zhu B; Kang BH; Gonzalez FJ; Peters JM
    Mol Cancer Ther; 2014 Apr; 13(4):1008-17. PubMed ID: 24464939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiopoietin-2 in Bone Marrow milieu promotes Multiple Myeloma-associated angiogenesis.
    Belloni D; Marcatti M; Ponzoni M; Ciceri F; Veschini L; Corti A; Caligaris Cappio F; Ferrarini M; Ferrero E
    Exp Cell Res; 2015 Jan; 330(1):1-12. PubMed ID: 25447443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.
    Kumar S; Witzig TE; Timm M; Haug J; Wellik L; Kimlinger TK; Greipp PR; Rajkumar SV
    Blood; 2004 Aug; 104(4):1159-65. PubMed ID: 15130943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
    Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
    Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-CATENIN pathway and nonsteroidal antiinflammatory drugs.
    Foreman JE; Sorg JM; McGinnis KS; Rigas B; Williams JL; Clapper ML; Gonzalez FJ; Peters JM
    Mol Carcinog; 2009 Oct; 48(10):942-52. PubMed ID: 19415698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis.
    Piqueras L; Reynolds AR; Hodivala-Dilke KM; Alfranca A; Redondo JM; Hatae T; Tanabe T; Warner TD; Bishop-Bailey D
    Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):63-9. PubMed ID: 17068288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The peroxisome proliferator-activated receptor-β/δ antagonist GSK0660 mitigates retinal cell inflammation and leukostasis.
    Capozzi ME; Savage SR; McCollum GW; Hammer SS; Ramos CJ; Yang R; Bretz CA; Penn JS
    Exp Eye Res; 2020 Jan; 190():107885. PubMed ID: 31758977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.